EMA "road map" calls for more collaborative approach to drug regulation
This article was originally published in Scrip
The European Medicines Agency (EMA) has outlined a vision of the future EU regulatory environment where regulators and industry start working together earlier on in the drug development process to improve the chances of approval, and information on discontinued drugs is shared with the scientific community to help avoid repetition of studies and reduce the drug development attrition rate.
You may also be interested in...
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.